MRNA VACCINE DEVELOPMENT

NIH Pandemic-Era Grants

Pandemic Era Grants

2024

↗ Live URL (may be dead)

Document text

Principal Investigator: KATERINA  ANDRIANOVA
Organization: FLAG BIO, INC.
Fiscal Year: 2024
Award: $594,566
Funding agency: National Institute of Allergy and Infectious Diseases

The contractor will develop mRNAFlag as a vaccine adjuvant.  mRNAFlag is an mRNA transcript that encodes for the deimmunized TLR5 agonist GP532.  mRNAFlag would be developed within the context of an influenza mRNA vaccine, using an A/California/07/2009(H1N1) hemagglutinin in an LNP formulation used by Moderna for its SARS-CoV-2 vaccine.

Terms: <2019-nCoV vaccine><Agonist><COVID-19 vaccine><California><Contractor><Dependence><Dose><Formulation><Grippe><H1N1><H1N1 Virus><Hemagglutinin><Immune response><Immunological response><In Vitro><Influenza><Influenza A Virus, H1N1 Subtype><Influenza HA><Influenza Hemagglutinin><Messenger RNA><Mice><Mice Mammals><Murine><Mus><Pharmacodynamics><RNA vaccine><RNA-based vaccine><SARS-CoV-2 vaccine><SARS-coronavirus-2 vaccine><Series><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe acute respiratory syndrome coronavirus 2 vaccine><Specificity><TIL3><TLR5><TLR5 gene><TLR5 receptor><Toll-Like Receptor 5><Toll/Interleukin-1 Receptor-Like Protein 3><Toxicology><Transcript><Vaccinated><Vaccine Adjuvant><Vaccines><Variant><Variation><anti-flu><anti-influenza><antiflu><cell transduction><cellular transduction><coronavirus disease 2019 vaccine><coronavirus disease-19 vaccine><de-immunization><de-immunize><deimmunization><deimmunize><design><designing><determine efficacy><develop a vaccine><develop vaccines><development of a vaccine><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><flu HA><flu hemagglutinin><flu infection><flu virus infection><host response><immune system response><immunoresponse><infected with flu><infected with flu virus><infected with influenza><infected with influenza virus><influenza infection><influenza viral HA><influenza viral hemagglutinin><influenza virus HA><influenza virus hemagglutinin><influenza virus infection><mRNA><mRNA lipid nano particle vaccine><mRNA vaccine><mRNA-LNP based vaccine><mRNA-LNP combination vaccines><mRNA-LNP vaccines><mRNA-based vaccine><mouse model><murine model><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><polypeptide><pre-clinical efficacy><preclinical efficacy><toll-5 receptor><transduced cells><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidates against SARS-CoV-2><vaccine development><vaccine for novel coronavirus><vaccines preventing COVID><vaccines to prevent COVID>